Follow the money
Share:
🩸 Follow the money: People with kidney failure rely on dialysis machines to remove toxins from their blood, but the tech is outdated and a hassle to move around. That’s why researchers are developing smaller options, like the AKTIV. They’re struggling to secure funding, which is no surprise, given the dialysis market is worth $26 billion a year. They don’t want change.
Share:
All tech. No filler.
Join 900,000+ people who stay ahead of the tech curve with The Current, delivered daily. No fluff, no BS.